Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 24
- DOI:
- 10.3760/cma.j.issn.0366-6999.2010.24.024
- Key Word:
- type 2 diabetes mellitus;valsartan;diabetic cardiomyopathy
Abstract： Background The development of diabetic cardiomyopathy is multifactorial. Insulin resistance (IR) and excessive activity of the renin-angiotensin system are confirmed reasons for diabetic cardiomyopathy. Renin-angiotensin system (RAS) inhibitors can reduce tissue Ang Ⅱ levels, with beneficial effects on cardiovascular function. Therefore, in type-2diabetes mellitus (T2DM), blockade of the RAS may have the function of protecting against diabetic cardiomyopathy through increasing insulin sensitivity and inhibiting excessive activity of RAS. However, this has not been confirmed.Methods The effect of valsartan, an angiotensin receptor blocker (ARB), on diabetic cardiomyopathy in the presence of T2DM was studied. Wistar rats with T2DM and T2DM treated with valsartan were studied. Glucose infusion rates (GIR),index of IR, heart weight, the heart weight-to-body weight ratio (HW/BW), myocardial apoptotic index, cardiac hydroxyprolin content, and cardiac tissue collagen type Ⅰ and collagen type Ⅲ content were measured.Results GIR in T2DM rats and T2DM rats treated with valsartan decreased (P ＜0.01). In T2DM rats treated with valsartan, heart weight, myocardial apoptotic index, cardiac hydroxyprolin content, and cardiac tissue collagen type Ⅰ and collagen type Ⅲ content were higher than in control rats, but lower than in T2DM rats. In rats with T2DM, GIR was negatively and significantly correlated with all the variables. However, in T2DM rats treated with valsartan or normal control rats, none of the correlations was significant.Conclusions In the presence of T2DM, diabetic cardiomyopathy is related with IR. Valsartan can not alleviate IR, but can protect against diabetic cardiomyopathy and remove the correlation between IR and diabetic cardiomyopathy.
- [1]Sechi LA,Rilli S,Carey RM,etc.The renin-angiotensin-aldosterone system, glucose metabolism and diabetes.[J].2005,16(3).
- [2]Ping H,Zhen-Chan L,Xiao-Dong P,etc.Insulin resistance, renal injury, renal 1-alpha hydroxylase, and bone homeostasis in aged obese rats.[J].2008,39(4).
- [3]Yoshida D,Shimamoto K,Ura N,etc.Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.[J].2004,22(10).
- [4]M, Müller,P, Fasching,R, Schmid,etc.Inhibition of paracrine angiotensin-converting enzyme in vivo: effects on interstitial glucose and lactate concentrations in human skeletal muscle.[J].1997,27(10).
- [5]J F, WOESSNER.The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid.[J].1961,93.
- [6]Lewis EJ,Pohl MA,Raz I,etc.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.[J].2001,345(12).
- [7]Saad MJ,Hansen H,Kahn CR,etc.Crosstalk between insulin and angiotensin II signalling systems (see comments)[J].1999,107(2).
- [8]Fang ZY,Prins JB,Marwick TH.Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.[J].2004,25(4).
- [9]P, Codinach Huix,R, Freixa Pamias.[Diabetic cardiomyopathy: concept, heart function, and pathogenesis].[J].2002,19(6).
- [10]Chang-Quan H,Qian X,Qun-Fang D,etc.Renal injury, abnormal vitamin d metabolism and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus.[J].2008,56(6).
- [11]R I, Hamby,S, Zoneraich,L, Sherman.Diabetic cardiomyopathy.[J].1974,229(13).
- [12]D, Feuvray.Diabetic cardiomyopathy.[J].2004,97(3).
- [13]Shirley Rubler,Joel Dlugash,Yusuf Ziya Yuceoglu,etc.New type of cardiomyopathy associated with diabetic glomerulosclerosis[J].1972,30(6).
- [14]Parving HH,Lehnert H,Brochner-Mortensen J,etc.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.[J].2001,345(12).
- [15]Mitch WE,Brenner BM,Remuzzi G,etc.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.[J].2001,345(12).
- [16]W J, Blaedel,J M, Uhl.Nature of materials in serum that interfere in the glucose oxidase-peroxidase-0-dianisidine method for glucose, and their mode of action.[J].1975,21.
- [17]Ding, An,Brian, Rodrigues.Role of changes in cardiac metabolism in development of diabetic cardiomyopathy.[J].2006,291(4).